Sign In
Buy INVA
$21.70
+0.350 (+1.64%)
At Close: Jun 03, 2026
Lilly (LLY) Gets CRL from FDA for Sintilimab in Lung Cancer
03:45pm, Friday, 25'th Mar 2022 Zacks Investment Research
Lilly (LLY) gets a complete response letter from the FDA for the biologics license application for sintilimab plus pemetrexed and platinum chemotherapy for treating first-line lung cancer.
Novartis' (NVS) Pluvicto Gets FDA Nod for Advanced Prostate Cancer
05:39pm, Thursday, 24'th Mar 2022 Zacks Investment Research
The FDA okays Novartis' (NVS) targeted radioligand therapy Pluvicto to treat PSMA-positive metastatic castration-resistant prostate cancer.
This group of stocks is flagging a rebound, and that's good news for the S&P 500, says technical analyst
01:05pm, Tuesday, 22'nd Mar 2022 MarketWatch
Where is the market going after last week's rally? Our call of the day from MKM's chief strategist is looking at healthy signals from the healthcare sector.
Merck (MRK) Stops Keytruda-Lynparza Combo Prostate Cancer Study
01:00pm, Wednesday, 16'th Mar 2022 Zacks Investment Research
Merck (MRK) decides to discontinue a late-stage prostate cancer study evaluating Keytruda in combination with AstraZeneca's Lynparza, following its failure to demonstrate a benefit in overall survival
Sanofi's (SNY) Breast Cancer Candidate Misses Goal in Study
04:31pm, Monday, 14'th Mar 2022 Zacks Investment Research
Sanofi's (SNY) phase II AMEERA-3 study, investigating amcenestrant in ER+/HER2- advanced/metastatic breast cancer, fails to meet the primary endpoint.
Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?
01:40pm, Monday, 14'th Mar 2022 Zacks Investment Research
Here is how Henry Schein (HSIC) and Innoviva (INVA) have performed compared to their sector so far this year.
Bayer (BAYRY) to Divest a Business Unit to Cinven for $2.6B
04:31pm, Friday, 11'th Mar 2022 Zacks Investment Research
Bayer (BAYRY) to sell off its Environmental Science Professional business unit to Cinven for $2.6 billion. The company plans to focus on core agricultural businesses.
Bayer (BAYRY) Files for Nubeqa's Label Expansion in US & EU
03:49pm, Thursday, 10'th Mar 2022 Zacks Investment Research
Bayer (BAYRY) submits regulatory applications to the FDA and the EMA, seeking approval for a new indication of Nubeqa for treating metastatic hormone-sensitive prostate cancer.
Zacks.com featured highlights include Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences
03:09pm, Monday, 07'th Mar 2022 Zacks Investment Research
Meridian Bioscience, Innoviva, Horace Mann Educators and Maravai LifeSciences are included in this blog.
1 Healthcare Stock That Could Fly Higher After a Strong Q4
04:23pm, Saturday, 05'th Mar 2022 The Motley Fool
This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.
1 Healthcare Stock That Could Fly Higher After a Strong Q4
11:23am, Saturday, 05'th Mar 2022
This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
12:35pm, Friday, 04'th Mar 2022 Zacks Investment Research
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
09:14am, Friday, 04'th Mar 2022
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.
Innoviva prices upsized convertible senior notes offering of $225M
12:58pm, Thursday, 03'rd Mar 2022 Seeking Alpha
Innoviva (INVA) priced its upsized offering of $225M principal amount of the 2.125% convertible senior notes due 2028; size of offering was increased from earlier announced…
Innoviva to raise $200M in convertible senior notes offering
12:43pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Innoviva (INVA) trades 6.7% down premarket after it plans to offer $200M in principal amount of convertible senior notes due 2028 in a private offering to qualified…
